Approximately 5% of the world's human population have an increased risk for developing
liver cancer and cirrhosis as a direct consequence of chronic infection with the hepatitis B …

Over the past century, a number of synthetic antimicrobial agents have been discovered and
developed, but drug resistance and toxicity are still the major hindrances to gaining …

Success in treating hepatitis B virus (HBV) infection with nucleoside analog drugs like
lamivudine is limited by the emergence of drug-resistant viral strains upon prolonged …

The phenylpropenamide derivatives AT-61 and AT-130 are nonnucleoside analogue
inhibitors of hepatitis B virus (HBV) replication. They inhibited the replication of wild-type …

Chronic delta hepatitis is a severe form of chronic liver disease caused by hepatitis delta
virus (HDV) infection superimposed on chronic hepatitis B or the hepatitis B surface antigen …

We recently reported that lactoferrin (LF), a milk protein belonging to the iron transporter
family, inhibits hepatitis C virus (HCV) infection in cultured human hepatocytes (PH5CH8) …

Despite the existence of vaccines, chronic hepatitis B virus (HBV) infection remains a major
health problem worldwide. Interferon therapy successfully controls infection in only a small …

Background/Aims: Interleukin-12 (IL-12) may be active against hepatitis B virus (HBV). The
objective of the study was to assess the tolerability, activity, pharmacokinetics, and …

Hepatitis B virus (HBV) infection is a major global health concern and is the most common
cause of chronic liver disease worldwide. The natural history and clinical outcomes of …

Prolonged treatment of chronic hepatitis B virus (HBV) infection with lamivudine ([−]-β-l-2′,
3′-dideoxy-3′ thiacytidine) or famciclovir may select for viral mutants that are drug …